Acylated GLP-1 derivative
Provided are a GLP-1(7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.
1. A derivative of a GLP-1(7-37) analogue or a pharmaceutically acceptable salt thereof, wherein the derivative is: N-ε 23 -[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(s)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl](Val 8 Glu 22 Lys 23 Arg 26,34 GLP-1(7-37)) peptide (M2), or N-ε 30 -[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(s)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl](Val 8 Glu 22 Lys 30 Arg 26,34 -GLP-1(7-37)) peptide (M4).
2. A method for preparing the derivative or a pharmaceutically acceptable salt thereof, comprising:
(1) mixing a solution in which the GLP-1 analogue according to claim 1 is dissolved with a solution in which the extension portion is dissolved;
(2) adjusting the pH to 4-5 to quench the reaction, standing until a precipitate is generated, and then collecting the precipitate; and
(3) adding TFA to the precipitate, and adjusting the pH to 7.5-8.5 to quench the reaction.
3. The method according to claim 2 , further comprising: adding triethylamine to a solution in which the GLP-1 analogue is dissolved, followed by mixing with a solution in which the extension portion is dissolved.
4. The method according to claim 2 , wherein the solution of the extension portion is dissolved by acetonitrile.
5. A pharmaceutical composition comprising the derivative or a pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable excipient.
6. A method for treating diabetes or diabetic complications, comprising: administering a prophylactically or therapeutically effective amount of the derivative or the pharmaceutically acceptable salt thereof according to claim 1 to a subject.
7. The method according to claim 6 , wherein the diabetic complication is diabetic nephropathy.
8. A method for reducing blood glucose, increasing glucose tolerance, reducing islet β-cell apoptosis, enhancing islet β-cell function, increasing islet β-cell number, and/or restoring islet β-cell glucose sensitivity, comprising: administering a therapeutically effective amount of the derivative or the pharmaceutically acceptable salt thereof according to claim 6 to a subject.
9. The method according to claim 8 , wherein said reducing blood glucose includes reducing fasting blood glucose and/or postprandial blood glucose.
10. A kit comprising: a container in which the pharmaceutical composition according to claim 5 is contained, and a package insert, wherein the package insert contains instructions for use of the pharmaceutical composition.
11. The kit according to claim 10 , further comprising a container containing one or more other medicaments.
12. The kit according to claim 11 , wherein the one or more other medicaments are other medicaments for treating diabetes or diabetic complications.
13. The derivative of a GLP-1(7-37) analogue or pharmaceutically acceptable salt thereof according to claim 1 wherein the derivative is N-ε 23 -[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(s)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl](Val 8 Glu 22 Lys 23 Arg 26,34 -GLP-1(7-37)) peptide (M2).
14. The derivative of a GLP-1(7-37) analogue or pharmaceutically acceptable salt thereof according to claim 1 wherein the derivative is N-ε 30 -[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(s)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl](Val 8 Glu 22 Lys 30 Arg 26,34 -GLP-1(7-37)) peptide (M4).